On October 6, 2026 Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be making an invited keynote presentation entitled "Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer" at the annual UK National Health Service (NHS) CancerCare Oncology Conference on Tuesday, October 6, at 11:30 a.m. UK time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CancerCare Conference brings together NHS leaders and clinicians, cancer alliances and other healthcare professionals from across the UK to discuss developments in cancer care, innovation and emerging treatments.

Dr. Bosch will discuss the new era of cancer vaccines, the need for personalized treatments, the unique capabilities of dendritic cell (DC) based cancer vaccines such as DCVax, clinical trial results, potential combination treatments and related matters. The slide deck will be posted on the Northwest Biotherapeutics website after the NHS conference.

(Press release, Northwest Biotherapeutics, OCT 6, 2026, View Source [SID1234673215])

On October 6, 2026 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, reported positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone. Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With the interim efficacy signal, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in the course of disease progression. Rather than treating patients after one or two anti-androgen agents, the modified protocol will enroll patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor. Patients will be randomized to enzalutamide alone or enzalutamide in combination with ENV-105. The protocol modification is intended to expand the eligible patient population and facilitate enrollment, with Kairos Pharma targeting completion of the Phase 2 trial in or before the fourth quarter of 2027.

"These interim results provide an important clinical signal for ENV-105 and support our strategy of targeting the mechanisms underlying drug resistance," said Chief Executive Officer of Kairos Pharma, Dr. John Yu. "The protocol modification will allow more patients to be eligible for the potential benefits of ENV-105 treatment while evaluating the therapy earlier in disease progression."

The findings further support Kairos Pharma’s strategy of targeting mechanisms associated with cancer drug resistance. ENV-105 targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy, providing the rationale for evaluating ENV-105 in combination with standard cancer therapies. The Phase 2 trial is designed to evaluate ENV-105, a first-in-class CD105 antibody, in men with metastatic prostate cancer resistant to standard hormone therapy, in combination with standard of care, apalutamide. Patients have been enrolled at Cedars-Sinai Medical Center, City of Hope and Huntsman Cancer Institute at the University of Utah.

(Press release, Kairos Pharma, OCT 6, 2026, View Source [SID1234673214])

On October 6, 2026 CatalYm reported that updated clinical results from its Phase 2 GDFATHER-NEO trial will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will feature updated findings from the Phase 2 GDFATHER-NEO trial (NCT06059547) and will include final pathological and radiological outcomes as well as event-free survival from the stratified, blinded trial evaluating visugromab versus placebo in combination with nivolumab as neoadjuvant treatment for patients with muscle-invasive bladder cancer (MIBC). These updated findings will provide further insights into the potential of GDF-15 inhibition in combination with immune checkpoint blockade.

In addition, two Trial in Progress presentations will provide an overview of the ongoing GDFATHER-NSCLC-02 (NCT07246863) and GDFATHER-HCC-01 (NCT07219459) Phase 2b trials, which are evaluating visugromab in second-line metastatic non-squamous non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), respectively. Together, these studies reflect CatalYm’s continued advancement of visugromab across multiple solid tumor indications.

Presentation Details

Rapid Oral Presentation – GDFATHER-NEO

Abstract #9061

Title: Final pathological and radiological outcomes and initial EFS from a blinded, exploratory Phase 2 trial of nivolumab ± visugromab in MIBC (GDFATHER-NEO)

Session: Rapid oral 1: Genitourinary tumours, renal and urothelial
Presentation Date and Time: October 24, 2026; 10:15 – 11:45 am CEST
Presenter: Andrea Necchi
Location: Bilbao Auditorium – Hall 3

Trials in Progress Poster Presentation – GDFATHER-NSCLC-02

Abstract #4316

Title: Phase 2b randomized, blinded, placebo-controlled trial investigating the efficacy and safety of visugromab plus nivolumab with or without docetaxel in second line metastatic non-squamous NSCLC: GDFATHER-NSCLC-02

Presentation Date and Time: October 26, 2026; 12:00 – 12:45 pm CET
Presenter: Martin Reck
Presentation Number: 2725TiP

Trials in Progress e-Poster Presentation – GDFATHER-HCC-01

Abstract #7627

Title: Phase 2b randomized, blinded trial to investigate the efficacy and safety of visugromab in combination with nivolumab and lenvatinib in unresectable or metastatic hepatocellular carcinoma after failure of first-line treatment including an anti-PD-(L)1 compound: GDFATHER-HCC-01

Presenter: Richard S. Finn

Presentation Number: 1761eTiP

About Visugromab

Visugromab is a monoclonal antibody that neutralizes Growth Differentiation Factor-15 (GDF-15), a locally acting immunosuppressant produced by tumors which fosters immunotherapy resistance and drives cachexia in people with cancer. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by re-enabling immune cell activation, proliferation, and induction of interferon-γ. In addition, visugromab also mitigates cancer cachexia, a severe condition affecting a significant number of advanced cancer patients by inhibiting the activation of the GFRAL pathway in the brainstem, a key driver of weight loss and appetite suppression in cancer patients.

(Press release, Catalym, OCT 6, 2026, View Source [SID1234673213])

On October 6, 2026 Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, reported that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients. Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design. We believe both programs have demonstrated the potential for allogeneic CAR-T cell therapies to deliver deep and durable responses, while meaningfully expanding access for patients who urgently need treatment options," said Rachel Haurwitz, PhD, president and CEO of Caribou. "Unfortunately, despite the progress we’ve made, the current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs. As a result, we’ve made the difficult decision to evaluate strategic alternatives and plan to discontinue further development of our allogeneic CAR-T cell therapy programs. We’re deeply grateful to the patients and families who placed their trust in us, the physicians and site teams who partnered with us, and every member of the Caribou team whose skill and commitment brought these programs this far and advanced the field of cell therapy."

Caribou’s Board of Directors approved initiating a process to evaluate strategic alternatives, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving Caribou and/or its assets. Wedbush Securities Inc. has been engaged as the company’s exclusive financial advisor to assist in the strategic evaluation process. Caribou has not set a timeline for the completion of review of strategic alternatives and does not intend to provide further updates unless and until the Board of Directors has approved a course of action, the review process is concluded, or other disclosure is otherwise determined to be appropriate. In conjunction with this announcement, Caribou plans to discontinue further clinical development activities and implement a substantial reduction in workforce, which is expected to be mostly complete in the fourth quarter of 2026.

As of June 30, 2026, Caribou had $113.8 million in cash, cash equivalents, and marketable securities.

About vispacabtagene regedleucel

Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design. To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy to demonstrate safety, efficacy, and durability on par with autologous CAR-T cell therapies. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for B-NHL.

About CB-011

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy evaluated in patients with relapsed or refractory multiple myeloma (r/r MM). To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection. Clinical data from the CB-011 CaMMouflage phase 1 trial has demonstrated the potential for deep, durable responses in patients with r/r MM. The FDA granted CB-011 RMAT, Fast Track, and Orphan Drug designations for r/r MM.

(Press release, Caribou Biosciences, OCT 6, 2026, View Source [SID1234673212])

On October 6, 2026 New Zealand’s advanced cell therapy company BioOra reported the National Party’s commitment to co‑invest $25 million to expand BioOra’s cell therapy manufacturing, research, and clinical facilities in Christchurch, New Zealand.

The commitment, set out in National’s health policy, "More medicines and earlier care", issued 6th October 2026, would support the production of CAR T-cell therapy here in New Zealand. The policy also proposes a national clinical trials target, a single front door for trials, and simpler approvals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We welcome this commitment. Building CAR T-cell and advanced cellular therapy manufacturing in New Zealand is about sovereign capability, creating skilled jobs, and growing the biotech industry in the South Island. This is about bringing the next generation of cancer treatment closer to home for New Zealanders", said BioOra Chief Executive John Robson.

"We have engaged constructively with a range of political parties across Parliament and have been encouraged by the support we’ve seen. Sovereign biomanufacturing is a long-term national asset, and we look forward to working with government to ensure that novel cell therapies are available to New Zealanders".

Malaghan Institute of Medical Research Chief Executive Professor Kjesten Wiig said the Malaghan welcomed National’s commitment to unlocking CAR T-cell therapy in New Zealand.

"Making CAR T-cell therapy a standard of care in the public health system has been the ultimate goal of our research and development of New Zealand’s first CAR T-cell therapy, one shared with BioOra".

"Investment in the research, development and delivery of advanced therapies in New Zealand is critical for our future health and prosperity as a nation".

BioOra’s VP of Clinical and Medical Affairs, James Oughton, said the proposed clinical trial measures would also be welcomed across the sector.

"Clinical trials are one of the main ways New Zealanders get access to innovative treatments. A clearer, faster, and more consistent approvals process would make New Zealand a more attractive place to run trials, and that benefits patients, clinicians, and researchers alike".

BioOra currently manufactures a CAR T-cell therapy (atla-cel) for ENABLE-2, a Phase II trial sponsored by the Malaghan Institute of Medical Research. Our goal is to make this therapy available to New Zealand patients after the trial, subject to regulatory approval. Any therapy BioOra produces will go through New Zealand’s independent regulatory and funding processes, including Medsafe, Pharmac, and the Health Technology Evaluation Pathway (HTEP). The trial is expected to close in Q2 2027, and BioOra is committed to providing public access pathways for access to their therapy.

(Press release, BioOra, OCT 6, 2026, View Source [SID1234673211])